Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Locally Advanced Pancreatic Cancer Market Size Likely To Evolve From 2025 Through 2034?
The market for locally advanced pancreatic cancer has experienced rapid growth in recent years. It is projected to expand from $0.95 billion in 2024 to $1.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. This historical increase can be attributed to several factors, including heightened awareness of pancreatic cancer, advancements in chemotherapy regimens, a rise in the adoption of targeted therapies, an increase in the incidence of pancreatic cancer, the formulation of combination treatment protocols, and enhanced supportive care options.
The market size for locally advanced pancreatic cancer is anticipated to experience substantial growth over the coming years. It is projected to expand to $1.56 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, a rise in the adoption of targeted therapies, an uptick in the incidence of pancreatic cancer, the formulation of combination treatment protocols, and improvements in supportive care options. Significant trends expected during this period include breakthroughs in immunotherapy, the continued development of targeted therapies, more sophisticated precision radiation techniques, enhanced diagnostic imaging, the integration of minimally invasive surgical approaches, the incorporation of artificial intelligence into treatment planning, and ongoing progress in combination therapy.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
What Are The Top Growth Drivers Impacting The Locally Advanced Pancreatic Cancer Market Outlook?
The escalating use of tobacco is anticipated to stimulate the expansion of the locally advanced pancreatic cancer markets moving forward. Tobacco is a plant whose leaves are processed into items such as cigarettes and cigars. It contains nicotine, an addictive substance linked to serious health problems like cancer and heart disease. The uptick in tobacco consumption is fueled by factors including simple availability, affordability, tobacco industry marketing, social acceptance in certain regions, and stress-induced smoking. Tobacco consumption represents a significant risk factor for the onset of locally advanced pancreatic cancer, as it contributes to a higher incidence of pancreatic malignancies. For example, in January 2024, data from Global Action to End Smoking, a US-based non-profit organization dedicated to research on ending the smoking epidemic, indicated that in 2022, approximately 62.9 million adults in the U.S. utilized tobacco, placing it 4th globally and 1st in the Americas. Furthermore, about 11.5% of U.S. adults (28.3 million) smoked cigarettes, with males exhibiting higher rates (13.1%) than females (10.1%). Consequently, the increase in tobacco consumption is a key driver for the growth of the locally advanced pancreatic cancer market.
What Are The Major Segments Identified In The Locally Advanced Pancreatic Cancer Market?
The locally advanced pancreatic cancermarket covered in this report is segmented –
1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
How Are Emerging Market Trends Shaping The Locally Advanced Pancreatic Cancer Industry Landscape?
Leading companies active in the locally advanced pancreatic cancer market are focusing their strategies on developing innovative therapeutic products, such as orphan drugs, designed to expand treatment options, improve patient outcomes, and address the significant unmet medical needs associated with this aggressive disease. These specialized orphan drugs are developed to treat rare conditions affecting a small patient population and benefit from incentives provided by authorities, including tax reductions and market exclusivity, to encourage their creation. A relevant example occurred in January 2025, when Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its compound, Elraglusib, a novel GSK-3β inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for its use in treating pancreatic ductal adenocarcinoma (PDAC), a type of locally advanced pancreatic cancer. This recognition underscores its potential to fill a critical treatment gap for this severe cancer, especially following promising Phase 2 trial results that showed significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.
Which Key Players Are Driving Competition In The Locally Advanced Pancreatic Cancer Market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Locally Advanced Pancreatic Cancer Industry Expansion?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Locally Advanced Pancreatic Cancer Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2025, By The Business Research Company
Pancreatic Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Pancreatic Cancer Diagnostic Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model